Novavax cheers top line RSV F vaccine retrial data, but investors aren’t buying it
admin 25th July 2017 Uncategorised 0After its RSV F vaccine candidate flunked a major phase 3 trial last September, Novavax has been trying to prove that it’s not the shot that’s the problem. The company sees hope in a new phase 2 trial, but the top-line results failed to restore confidence among investors.
More: Novavax cheers top line RSV F vaccine retrial data, but investors aren’t buying it
Source: fierce